Table 4 Commercially available PD-L1 IHC assays
From: Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016
BMS | Merck | Roche | Astra Zeneca | |
|---|---|---|---|---|
mAb clone | 28-8 | 22C3 | SP142 | SP263 |
Automated | Yes | Yes | Yes | Yes |
Diagnostic partner | Dako | Dako | Ventana | Ventana |
Machine | Link 48 | Link 48 | Benchmark ULTRA | Benchmark ULTRA |
Scoring | Tumor cells (membrane) | Tumor cells (membrane) | Tumor cells/or immune (membrane) | Tumor cells (membrane) |
Positive cutoff | ≥ 5% (also studied ≥ 1% and ≥ 10% thresholds | ≥ 1% for trial enrollment Other analysis at > 50% | TC3 (> 50%) or IC3 (> 10%) TC2/3 or IC2/3 (> 5%) TC 1/2/3 or IC 1/2/3 (> 1%) TC0 and IC0 (0%) | ≥ 25% |